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TABLE S1. Activity of 5,6-dichloro-1-phenyl-benzotriazole amides(5a-d and 7a-h) against 
viruses representative of positive-sense, single-stranded RNAs (ssRNA+): i) Retroviridae: 
HIV-1; ii) Flaviviridae: YFV and BVDV; iii) Picornaviridae: CV-B5 and Sb-1. Viruses 
representative of negative-sense, single-stranded RNAs (ssRNA-); i) Rhabdoviridae: VSV. Virus 
representative of double-stranded RNAs (dsRNA): Reoviridae: Reo-1. DNA virus 
representatives: i) Poxviridae: VV; ii) Herpesviridae: HSV-1. Efavirenz, 2’-C-methyl-guanosine, 
and Pleconarilwere used as reference inhibitors.Data represent mean values ± SD for three 
independent determinations. For values where SD is not shown, variation among duplicate 
samples was less than 15%.Efavirenz (EFV), 2’-C-methyl-guanosine (2MG), and Pleconaril 
(PCL) were used as reference inhibitors. 
Cpd 
MT-4 
cells 
HIV-1IIIB 
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CC50
a EC50
b CC50
c EC50
d CC50
e EC50
f EC50
g CC50
h EC50
i EC50
j 
1a >100 >100 >100 75 >100 >100 >100 >100 85 >100 
5a 35 >35 43 >43 53 >53 >53 30 17 >30 
5b 28 >28 >100 >100 54 >54 >54 30 >30 >30 
  
aCompound concentration (µM) required to reduce the proliferation of mock-infected MT-4 cells by 50%, as determined by the 
MTT method. bCompound concentration (µM) required to achieve 50% protection of MT-4 cells from HIV-1 induced 
cytopathogenicity, as determined by the MTT method. cCompound concentration (µM) required to reduce the viability of 
mock-infected MDBK cells by 50%, as determined by the MTT method. dCompound concentration (µM) required to achieve 50% 
protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. eCompound concentration 
(µM) required to reduce the viability of mock-infected BHK cells by 50%, as determined by the MTT method. fCompound 
concentration (µM  required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by 
the MTT method. gCompound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced 
cytopathogenicity, as determined by the MTT method. hCompound concentration (µM) required to reduce the viability of 
mock-infected VERO-76 cells by 50%. as determined by the MTT method. iCompound concentration (µM) required to reduce 
the plaque number of CV-B5 by 50% in VERO-76 monolayers. jCompound concentration (µM) required to reduce the plaque 
number of Sb-1, VSV, VV and HSV-1 by 50% in VERO-76 monolayers.  
5c 60 >60 >100 >100 >100 >100 >100 10 9 >100 
5d 35 >35 14 >14 16 >16 >16 20 >20 >20 
7a >100 >100 >100 >100 44 >44 >44 >100 >100 >100 
7b >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
7c 33 >33 >100 >100 >100 >100 >100 >100 >100 >100 
7d 77 >77 >100 >100 >100 78 >100 90 >90 >90 
7e >100 >100 >100 >100 96 >96 >96 >100 >100 >100 
7f >100 >100 >100 >100 84 >84 >84 >100 >100 >100 
7g >100 >100 >100 >100 >100 >100 >100 9  >90 >90 
7h >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref Cpd 
EFV 40 
0.002 ± 
0.0002 
        
2MG   >100 
1.1 ± 
0.1 
>100 
1.9 ± 
0.1 
0.7 ± 0.2    
PCL        
>10
0 
0.005 ± 
0.001 
 
  
TABLE S2. Activity of 5,6-dichloro-2-phenyl-benzotriazole amides(6a-h and 8a-h), and 
5,6-dichloro-2-phenyl-benzotriazole urees(10a-k) against viruses representative of positive-sense, 
single-stranded RNAs (ssRNA+): i) Retroviridae: HIV-1; ii) Flaviviridae: YFV and BVDV; iii) 
Picornaviridae: CV-B5 and Sb-1. Viruses representative of negative-sense, single-stranded RNAs 
(ssRNA-); i) Rhabdoviridae: VSV. Virus representative of double-stranded RNAs (dsRNA): Reoviridae: 
Reo-1. DNA virus representatives: i) Poxviridae: VV; ii) Herpesviridae: HSV-1. For values where SD is 
not shown, variation among duplicate samples was less than 15%.Efavirenz (EFV), 
2’-C-methyl-guanosine (2MG), and Pleconaril (PCL) were used as reference inhibitors. 
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CC50
a EC50
b CC50
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f EC50
g CC50
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i EC50
j 
1b 52 >52 ≥100 20 >100 >100 >100 >100 >100 >100 
6a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
6b >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
6c >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
6d 33 >33 100 >100 72 >72 >100 >100 >100 >100 
6e 15 >15 72 >72 26 >26 >26 >100 61 >100 
6f 24 >24 84 >84 62 >62 >26 >100 33 >100 
8a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
8b >100 >100 >100 >100 >100 73 >100 >100 >100 >100 
8c >100 >100 >100 >100 >100 >100 >100 >100 14 >100 
8d 63 >63 >100 35 35 >35 >35 80 >80 >80 
8e >100 >100 >100 4 68 >68 >68 >100 >100 >100 
8f >100 >100 >100 60 >100 >100 >100 80 >100 >100 
  
aCompound concentration (µM) required to reduce the proliferation of mock-infected MT-4 cells by 50%, as determined by the 
MTT method. bCompound concentration (µM) required to achieve 50% protection of MT-4 cells from HIV-1 induced 
cytopathogenicity, as determined by the MTT method. cCompound concentration (µM) required to reduce the viability of 
mock-infected MDBK cells by 50%, as determined by the MTT method. dCompound concentration (µM) required to achieve 50% 
protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method. eCompound concentration 
(µM) required to reduce the viability of mock-infected BHK cells by 50%, as determined by the MTT method. fCompound 
8g >100 >100 >100 28 >100 >100 >100 >100 >100 >100 
8h >100 >100 >100 11 >100 >100 >100 >100 >100 >100 
10a >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10b >100 >100 78 >78 40 >40 >40 30 >30 >30 
10c >100 >100 >100 >100 >100 >100 >100 90 >95 >95 
10d >100 >100 >100 >100 71 >71 >71 90 >90 >90 
10e >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10f >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10g >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10h >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10i >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10j >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
10k >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 
Ref Cpd 
EFV 40 
0.002 ± 
0.0002 
        
2MG   >100 
1.1 ± 
0.1 
>100 
1.9 ± 
0.1 
0.7 ± 
0.2 
   
PCL        >100 
0.005 ± 
0.001 
 
  
concentration (µM  required to achieve 50% protection of BHK cells from YFV-induced cytopathogenicity, as determined by 
the MTT method. gCompound concentration (µM) required to achieve 50% protection of BHK cells from Reo-1-induced 
cytopathogenicity, as determined by the MTT method. hCompound concentration (µM) required to reduce the viability of 
mock-infected VERO-76 cells by 50%. as determined by the MTT method. iCompound concentration (µM) required to reduce 
the plaque number of CV-B5 by 50% in VERO-76 monolayers. jCompound concentration (µM) required to reduce the plaque 
number of Sb-1, VSV, VV and HSV-1 by 50% in VERO-76 monolayers.  
 
Figure S1.Inhibition of RSV (m.o.i = 1) by addition of 20 M of compound 10d (black filled circles), 
10b (green filled circles), and 8d (red filled circles) at different times. Data for untreated virus (open 
circles) and for addition of 6-azauridine (filled squares) are also shown for comparison. Data represent 
mean values from two independent determinations; variation among duplicate samples was less than 
15%. Data for 10b and 8d were obtained under the same conditions employed for 10d (see main text, 
Materials and Methods section). 
 
Figure S2.Quantitative dose-response cell-to-cell fusion assay using the DSP-chimeric reporter 
proteins and the ViviRenrenilla luciferase substrate in the presence of compounds10d (black filled 
symbols), 10b (green filled symbols), and 8d (red filled symbols). The MeV (Measles Virus) F and H 
glycoprotein expression constructs (open symbols) were included for selectivity control. Reported 
values are normalized for DMSO-treated samples and are expressed as the mean of three experiments ± 
standard deviation. The EC50 valuesfor the three compounds, obtained by 4-parameter variable slope 
regression fitting, are: 3.2 M for 10d, 3.9 M for 10b, and 4.5 M for 8d, respectively. Data for 10b 
and 8d were obtained under the same conditions employed for 10d (see main text, Materials and 
Methods section). 
 
